1.北京中医药大学第三附属医院,北京市朝阳区安定门外小关街51号,100029
2.北京中医药大学
3.北京中医药大学东方医院
15810104902@163.com
收稿:2024-11-28,
修回:2025-03-18,
纸质出版:2025-05-17
移动端阅览
聂晶,庞瑞,钱灵娇等.加味过敏煎对轻中度特应性皮炎心火脾虚证患者中医证候和生活质量的影响——一项随机、双盲、安慰剂对照试验[J].中医杂志,2025,66(10):1031-1037.
NIE Jing,PANG Rui,QIAN Lingjiao,et al.Effects of Modified Guomin Decoction (加味过敏煎) on Traditional Chinese Medicine Syndromes and Quality of Life in Patients with Mild to Moderate Atopic Dermatitis of Heart Fire and Spleen Deficiency Pattern:A Randomized,Double-Blind,Placebo-Controlled Trial[J].Journal of Traditional Chinese Medicine,2025,66(10):1031-1037.
聂晶,庞瑞,钱灵娇等.加味过敏煎对轻中度特应性皮炎心火脾虚证患者中医证候和生活质量的影响——一项随机、双盲、安慰剂对照试验[J].中医杂志,2025,66(10):1031-1037. DOI: 10.13288/j.11-2166/r.2025.10.010.
NIE Jing,PANG Rui,QIAN Lingjiao,et al.Effects of Modified Guomin Decoction (加味过敏煎) on Traditional Chinese Medicine Syndromes and Quality of Life in Patients with Mild to Moderate Atopic Dermatitis of Heart Fire and Spleen Deficiency Pattern:A Randomized,Double-Blind,Placebo-Controlled Trial[J].Journal of Traditional Chinese Medicine,2025,66(10):1031-1037. DOI: 10.13288/j.11-2166/r.2025.10.010.
目的
2
观察加味过敏煎治疗轻中度特应性皮炎心火脾虚证患者的临床疗效及安全性,并探讨其可能作用机制。
方法
2
采用随机、双盲、安慰剂对照研究方法,将72例轻中度特应性皮炎心火脾虚证患者随机分为治疗组和对照组各36例。治疗组口服加味过敏煎颗粒配合外用维生素E乳,对照组口服安慰剂颗粒配合外用维生素E乳,均每天2次,疗程为4周。比较两组患者临床疗效,治疗前后的中医证候评分、瘙痒程度视觉模拟评分法(VAS)评分、皮肤病生活质量指数(DLQI)评分、特应性皮炎积分指数(SCORAD)评分,以及血清学指标[白细胞介素33(IL-33)、白细胞介素1β(IL-1β)、免疫球蛋白E(IgE)、肿瘤坏死因子α(TNF-α)]水平,并进行安全性评价。
结果
2
治疗组和对照组临床总有效率分别为77.78%(28/36)、38.89%(14/36),痊愈率分别为19.44%(7/36)、2.78%(1/36),治疗组临床疗效优于对照组(
P
<0.05)。与本组治疗前比较,治疗组治疗后中医证候总评分及红斑、水肿、丘疹、鳞屑、苔癣样变、瘙痒、烦躁、失眠、腹胀、体倦/疲劳评分均降低,VAS评分、DLQI评分、SCORAD评分和血清IgE、IL-33水平亦降低(
P
<0.05或
P
<0.01)。两组治疗后比较,上述指标除中医证候失眠评分外,其余指标结果治疗组均低于对照组(
P
<0.05)。两组均未发生不良事件。
结论
2
加味过敏煎治疗轻中度特应性皮炎心火脾虚证可显著减轻患者瘙痒程度,改善中医证候,提高生活质量及临床疗效,且安全性好,其作用机制可能与减轻免疫反应有关。
Objective
2
To observe the clinical efficacy and safety of
Modified Guomin Decoction
(加味过敏煎, MGD) in patients with mild to moderate atopic dermatitis (AD) of the tradition
al Chinese medicine (TCM) pattern of heart fire and spleen deficiency, and to explore its possible mechanisms.
Methods
2
In this randomized, double-blind, placebo-controlled study, 72 patients with mild to moderate AD and the TCM pattern of heart fire and spleen deficiency were randomly divided into a treatment group and a control group, with 36 cases in each group. The treatment group received oral MGD granules combined with topical vitamin E emulsion, while the control group received oral placebo granules combined with topical vitamin E treatment. Both groups were treated twice daily for 4 weeks. Clinical efficacy, TCM syndrome scores, Visual Analogue Scale (VAS) for pruritus, Dermatology Life Quality Index (DLQI) scores, Scoring Atopic Dermatitis (SCORAD) and serum biomarkers, including interleukin-33 (IL-33), interleukin-1β (IL-1β), immunoglobulin E (IgE), and tumor necrosis factor-α (TNF-α) were compared before and after treatment. Safety indexes was also assessed.
Results
2
The total clinical effective rates were 77.78% (28/36) in the treatment group and 38.89% (14/36) in the control group, with cure rates of 19.44% (7/36) and 2.78% (1/36), respectively. The treatment group showed significantly better clinical outcomes compared to the control group (
P
<0.05). The treatment group exhibited significant reductions in total TCM syndrome scores, including erythema, edema, papules, scaling, lichenification, pruritus, irritability, insomnia, abdominal distension, and fatigue scores, as well as reductions in VAS, DLQI, SCORAD, and serum IgE and IL-33 levels (
P
<0.05 or
P
<0.01). Compared to the control group, the treatment group had significantly better improvements in all indicators except for insomnia (
P
<0.05). No adverse events occurred in either group.
Conclusion
2
MGD is effective and safe in treating mild to moderate AD patients with heart fire and spleen deficiency pattern. It significantly alleviates pruritus, improves TCM syndromes and quality of life, and enhances clinical efficacy, possibly through modulation of immune responses.
TIAN J , ZHANG D , YANG Y , et al . Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study [J]. Br J Dermatol , 2023 , 190 ( 1 ): 55 - 61 .
GONZALEZ-URIBE V , VIDAURRI-DE LA CRUZ H , GOMEZ-NUNEZ A , et al . Comorbidities & burden of disease in atopic dermatitis [J]. Asian Pac J Allergy Immunol , 2023 , 41 ( 2 ): 97 - 105 .
SCHULER CF 4th , BILLI AC , MAVERAKIS E , et al . Novel insights into atopic dermatitis [J]. J Allergy Clin Immunol , 2023 , 151 ( 5 ): 1145 - 1154 .
赵欣楠 , 李雪 , 任雪雯 , 等 . 李元文从肝脾论治小儿特应性皮炎经验 [J]. 中医杂志 , 2023 , 64 ( 18 ): 1857 - 1861 .
中华医学会皮肤性病学分会免疫学组 . 中国特应性皮炎诊疗指南(2020版) [J]. 中华皮肤科杂志 , 2020 , 53 ( 2 ): 81 - 88 .
STALDER JF , TAIEB A , ATHERTON DJ , et al . Severity scoring of atopic dermatitis: the SCORAD index.Consensus report of the European Task Force on Atopic Dermatitis [J]. Dermatology , 1993 , 186 ( 1 ): 23 - 31 .
世界中医药学会联合会皮肤科专业委员会 . 国际中医临床实践指南:特应性皮炎 [J]. 世界中医药 , 2021 , 16 ( 16 ): 2367 - 2370 .
全国中医标准化技术委员会 . 中医临床诊疗术语 第2部分:证候 [S]. 北京 : 中国标准出版社 , 2021 : 201 - 230 .
李元文 , 张丰川 , 周德瑛 . 辨证治疗特应性皮炎35例 [J]. 北京中医药大学学报 , 2002 , 25 ( 5 ): 69 - 70 .
朱榴燕 , 姜敏 , 马莉 , 等 . 湿包护理对于结节性痒疹的疗效评估 [J]. 实用皮肤病学杂志 , 2024 , 17 ( 6 ): 367 - 369 .
万霞 , 李赞华 , 刘建平 . 临床研究中的样本量估算:(1)临床试验 [J]. 中医杂志 , 2007 , 48 ( 6 ): 504 - 507 .
REICH A , HEISIG M , PHAN NQ , et al . Visual analogue scale: evaluation of the instrument for the assessment of pruritus [J]. Acta Derm Venereol , 2012 , 92 ( 5 ): 497 - 501 .
FINLAY AY , KHAN GK . Dermatology Life Quality Index (DLQI):a simple practical measure for routine clinical use [J]. Clin Exp Dermatol , 1994 , 19 ( 3 ): 210 - 216 .
国家中医药管理局 . 中医病证诊断疗效标准 [M]. 南京 : 南京大学出版社 , 1994 : 263 - 265 .
FACHERIS P , JEFFERY J , DEL DUCA E , et al . The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment [J]. Cell Mol Immunol , 2023 , 20 ( 5 ): 448 - 474 .
范子怡 , 孙占学 , 张慧丽 , 等 . 连苓方联合他克莫司软膏治疗青少年特应性皮炎发作期心火脾虚证随机对照临床观察 [J]. 中医杂志 , 2024 , 65 ( 23 ): 2442 - 2449 .
李腾飞 . 凉血消积汤治疗儿童期特应性皮炎的临床观察及对血清IgE的影响 [D]. 哈尔滨 : 黑龙江中医药大学 , 2023 .
AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel . Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations [J]. Ann Allergy Asthma Immunol , 2024 , 132 ( 3 ): 274 - 312 .
AKDIS CA , ARKWRIGHT PD , BRUGGEN MC , et al . Type 2 immunity in the skin and lungs [J]. Allergy , 2020 , 75 ( 7 ): 1582 - 1605 .
MURAKAMI-SATSUTANI N , ITO T , NAKANISHI T , et al . IL-33 promotes the induction and maintenance of Th2 immune responses by enhancing the function of OX40 ligand [J]. Allergol Int , 2014 , 63 ( 3 ): 443 - 455 .
SCHULER CF 4th , GUDJONSSON JE . IL-33 antagonism does not improve chronic atopic dermatitis: what can we learn? [J]. J Allergy Clin Immunol , 2022 , 150 ( 6 ): 1410 - 1411 .
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号